Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies
Status:
Completed
Trial end date:
2021-08-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and PK/PD
of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered twice weekly for 2
weeks via IP bolus injection for the treatment of patients with peritoneal malignancies,
including but not limited to peritoneal carcinomatosis, malignant ascites, pseudomyxoma
peritonei, and peritoneal mesothelioma.